Orris

Recent guidelines for treating Falciparum Malaria

Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"Malaria, Falciparum"[MeSH Terms] AND "Practice Guideline"[pt]

Searching PubMed

"Malaria, Falciparum"[MeSH Terms] AND treatment

Searching the Web

WHO Guidelines for malaria 2025 falciparum malaria treatment severe uncomplicated artesunate ACT

Reading Web Page

https://www.who.int/publications/i/item/guidelines-for-malar…

Reading File
Reading File
Searching PubMed

falciparum malaria artesunate severe treatment

Current approach to Plasmodium falciparum malaria treatment

Treat confirmed or strongly suspected falciparum malaria promptly. First determine whether it is uncomplicated or severe, because severe malaria is a medical emergency requiring parenteral therapy and hospital-level care.

1. Uncomplicated falciparum malaria

First-line treatment: a 3-day artemisinin-based combination therapy (ACT). WHO recommends an ACT for adults and children, including infants, breastfeeding women, and women in the second and third trimesters of pregnancy. Options are selected according to local efficacy and resistance surveillance:
  • Artemether-lumefantrine (AL)
  • Artesunate-amodiaquine (AS-AQ)
  • Artesunate-mefloquine (AS-MQ)
  • Dihydroartemisinin-piperaquine (DHA-PPQ)
  • Artesunate-sulfadoxine-pyrimethamine (AS-SP), only where the partner drug remains effective
  • Artesunate-pyronaridine (AS-PY)
The current WHO malaria guideline lists these ACT options and emphasizes country-specific selection based on local resistance patterns. Oral artemisinin monotherapy must not be used, because it promotes artemisinin resistance.
Transmission-blocking primaquine: In appropriate settings, WHO recommends adding a single low dose of primaquine, 0.25 mg base/kg, to ACT to reduce gametocyte transmission, especially in lower-transmission or elimination settings. This is not “radical cure” therapy and is not routinely needed to prevent relapse in falciparum malaria, since P. falciparum has no dormant liver hypnozoites. Do not give primaquine during pregnancy; follow national policy for infants and other special populations. The WHO consolidated recommendations state that G6PD testing is not required before this single gametocytocidal dose.
Pregnancy
  • Second and third trimester: ACT is recommended.
  • First trimester: follow current national or WHO guidance. Artemether-lumefantrine has the largest clinical experience. Some ACTs, including AS-SP and AS-PY, are not recommended in the first trimester in the WHO guidance.
  • Never use primaquine in pregnancy.
Chloroquine: It is inappropriate for most falciparum infections because resistance is widespread. It remains an option only if infection was acquired in a documented chloroquine-sensitive area, such as Haiti, the Dominican Republic, or limited areas of Central America west of the Panama Canal, as described in CDC treatment guidance.

2. Severe falciparum malaria

Treat as severe malaria if there is impaired consciousness/coma, repeated seizures, shock, respiratory distress or metabolic acidosis, acute kidney injury, jaundice with organ dysfunction, severe anemia, hypoglycemia, abnormal bleeding, hemoglobinuria, pulmonary edema, or high parasite density. It can deteriorate rapidly.
First-line: intravenous artesunate, immediately.
  • WHO regimen: IV artesunate 2.4 mg/kg at 0, 12, and 24 hours, then once daily until oral medicine can be taken.
  • WHO uses 3 mg/kg per dose in children weighing <20 kg.
  • Do not delay artesunate while awaiting referral, repeat microscopy, or intensive-care transfer.
  • If IV artesunate is unavailable, give IM artesunate or IM artemether where available, and urgently arrange transfer. IV quinine is a fallback when artemisinin derivatives cannot be obtained, but has more toxicity and monitoring burden.
After the patient improves and can take oral treatment, complete a full 3-day ACT course. Parenteral artesunate alone is insufficient because it is rapidly eliminated. In the United States, CDC advises IV artesunate at 0, 12, and 24 hours, daily continuation if needed, then a full oral follow-on course once parasitemia is low and oral treatment is tolerated. See the CDC severe-malaria protocol.
Supportive management
  • Admit and monitor closely, often in a high-dependency or intensive-care setting.
  • Monitor glucose frequently and correct hypoglycemia.
  • Serial thick and thin smears or parasite counts, typically at least daily.
  • Careful fluid balance: avoid routine aggressive fluid boluses, which can precipitate pulmonary edema.
  • Treat seizures, acidosis, renal failure, shock, severe anemia, and bacterial co-infection when indicated.
  • Exchange transfusion is not recommended as routine adjunctive treatment.
  • After IV artesunate, monitor for delayed hemolysis, particularly with high initial parasitemia. CDC recommends laboratory follow-up after discharge.

3. Resistance and treatment failure

Artemisinin partial resistance, reflected by delayed parasite clearance, is established in parts of Southeast Asia and has been detected in increasing areas of Africa. ACTs remain the standard treatment, but the partner drug and regimen must be chosen from local surveillance and national malaria-program recommendations. Persistent fever or parasitemia should prompt reassessment for adherence, vomiting or poor absorption, incorrect diagnosis/species identification, reinfection, recrudescence, and resistance.
Recent systematic reviews include Fox et al., 2025, Cochrane review, PMID: 41085194 on pyronaridine-artesunate, and de Freitas et al., 2024, systematic review/meta-analysis, PMID: 37772768 on artesunate-mefloquine. Their relevance depends on regional resistance patterns and available formulations.

Practical bottom line

Clinical situationRecommended treatment
Uncomplicated falciparum malaria3-day ACT selected by local policy and resistance data
Severe falciparum malariaImmediate IV artesunate, then full oral ACT when able
Falciparum in pregnancyACT in 2nd/3rd trimester; first trimester regimen guided by current national/WHO policy; no primaquine
Need to reduce transmissionConsider one low dose primaquine with ACT, except in pregnancy and where national guidance differs
Artemisinin monotherapyDo not use
This is a guideline summary, not an individual prescription. Choice and dose depend on body weight, age, pregnancy, country of acquisition, prior prophylaxis, parasitemia, severity, vomiting, renal/hepatic function, and local drug susceptibility.
This is a shared conversation. Sign in to Orris to start your own chat.